Rhythm Pharmaceuticals, Inc. Overview
Pro stress-test →Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases. The company is dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction, with research focusing on the melanocortin-4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight.
Strategic Profile
Pro stress-test →The company generated net product revenues of $194.8 million for the full year 2025 from global sales of IMCIVREE, compared to $130.1 million in 2024. The company has a supplemental New Drug Application (sNDA) under FDA review with a PDUFA goal date of March 20, 2026, and is also pursuing European Medicines Agency approval for setmelanotide in acquired hypothalamic obesity. The company is investing in next-generation MC4R agonist development, U.S. commercial support for the HO launch, and building operations in Japan.
Competitive Landscape
Pro stress-test →Rhythm focuses on the MC4R pathway for rare genetic obesity and metabolic disorders, a specialized niche within the broader obesity treatment market. Primary competition exists from other obesity and metabolic dysfunction therapeutics developers, though the rare genetic disease segment remains less crowded than the broader GLP-1 obesity market.
Industry Context
Rhythm Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals - Rare Disease & Obesity.
Key facts
Founded: N/A · Headquarters: Boston, US · Employees: N/A · Revenue: $194.8M (2025) · Market cap: N/A